Four oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Commentary|Videos|February 26, 2026
RB-1355 Shows Safety in Lymphoma Trials
Author(s)Paolo Strati, MD
Fact checked by: Paige Britt
Trial finds CAR‑T approach shows minimal CRS and no neurotoxicity or prolonged cytopenia, enabling safer treatment for older, frail patients.
Advertisement
In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, explained the adverse events associated with RB-1355 and how they compare to other lymphoma treatments.
Advertisement
Related to this article
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
2
Key Takeaways From DeLLphi-305 at ESMO 2026
3
Surprising OS and PFS Findings With Tarlatamab/Durvalumab in DeLLphi-305
4
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
5